Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linagliptin and Basal Insulin in Hospitalized T2DM
NCT03051243Phase 3Unknown
- Sponsor
- Rabin Medical Center
- Start
- Oct 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Rabin Medical Center. Primary endpoint: Percentage of patients with mean blood glucose levels at 6 months. Status: unknown.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03051243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03051243.